Crsp stock price is benefiting from strong sector

CRSP stock price is benefiting from strong sector rotation in Nasdaq biotech components, with weekly gains of 3.2% and above-average speculative call option activity. Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes. Meanwhile, Pfizer has made and is making key growth moves. The company's benefiting from its purchase of oncology company Seagen, as that biotech's four commercialized drugs are delivering quarterly revenue growth and putting Pfizer on the path to becoming an oncology giant by the early 2030s. And just recently Pfizer said it would buy biotech Metsera , offering it a weight loss drug portfolio and opening the door to a market that's marching toward $100 billion. CRSP stock price advanced 2.6% today on news of new research agreements with prominent pharma companies, reinforcing medium-term growth expectations.